Recently stock market analysts have updated their consensus ratings on shares of Abeona Therapeutics Inc. (ABEO). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/20/2016 – Abeona Therapeutics Inc. had its “buy” rating reiterated by analysts at Rodman & Renshaw. They now have a USD 17 price target on the stock.

12/15/2015 – Maxim Group began new coverage on Abeona Therapeutics Inc. giving the company a “buy” rating. They now have a USD 6 price target on the stock.

07/20/2015 – MLV & Co began new coverage on Abeona Therapeutics Inc. giving the company a “buy” rating. They now have a USD 15 price target on the stock.

Abeona Therapeutics Inc. has a 50 day moving average of 2.72 and a 200 day moving average of 3.15. The stock’s market capitalization is 78.88M, it has a 52-week low of 2.05 and a 52-week high of 10.85.

The share price of the company (ABEO) was down -0.41% during the last trading session, with a high of 2.45 and the volume of Abeona Therapeutics Inc. shares traded was 50133.

View other investors thoughts on Abeona Therapeutics Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.